Free Trial

4D Molecular Therapeutics (FDMT) Competitors

4D Molecular Therapeutics logo
$4.28 -0.07 (-1.61%)
Closing price 04:00 PM Eastern
Extended Trading
$4.38 +0.09 (+2.22%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FDMT vs. GHRS, SNDX, IMNM, GYRE, VIR, DNA, XERS, REPL, PHAR, and SANA

Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), Gyre Therapeutics (GYRE), Vir Biotechnology (VIR), Ginkgo Bioworks (DNA), Xeris Biopharma (XERS), Replimune Group (REPL), Pharming Group (PHAR), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

4D Molecular Therapeutics vs. Its Competitors

4D Molecular Therapeutics (NASDAQ:FDMT) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

4D Molecular Therapeutics currently has a consensus target price of $29.56, indicating a potential upside of 590.55%. GH Research has a consensus target price of $32.00, indicating a potential upside of 101.64%. Given 4D Molecular Therapeutics' higher possible upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than GH Research.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4D Molecular Therapeutics
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
GH Research
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, GH Research had 4 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 8 mentions for GH Research and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.37 beat GH Research's score of 0.35 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
4D Molecular Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GH Research
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

4D Molecular Therapeutics has a beta of 2.81, indicating that its stock price is 181% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

GH Research has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. GH Research's return on equity of -19.20% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
4D Molecular Therapeutics-767,126.06% -33.26% -30.68%
GH Research N/A -19.20%-18.40%

GH Research has lower revenue, but higher earnings than 4D Molecular Therapeutics. GH Research is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular Therapeutics$40K4,957.31-$160.87M-$3.18-1.35
GH ResearchN/AN/A-$38.96M-$0.79-20.09

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 41.6% of GH Research shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

GH Research beats 4D Molecular Therapeutics on 8 of the 14 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDMT vs. The Competition

Metric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$201.51M$2.45B$5.61B$9.11B
Dividend YieldN/A1.79%5.24%4.01%
P/E Ratio-1.353.9119.7619.92
Price / Sales4,957.31729.02430.8999.65
Price / CashN/A165.3637.4658.16
Price / Book0.394.608.045.49
Net Income-$160.87M$31.26M$3.18B$250.27M
7 Day Performance4.52%4.80%3.72%4.78%
1 Month Performance-1.83%4.19%3.72%7.20%
1 Year Performance-83.40%-2.89%29.92%17.27%

4D Molecular Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDMT
4D Molecular Therapeutics
2.2707 of 5 stars
$4.28
-1.6%
$29.56
+590.6%
-81.3%$201.51M$40K-1.35120
GHRS
GH Research
2.033 of 5 stars
$15.01
+0.7%
$32.00
+113.2%
+41.2%$776MN/A-19.0010
SNDX
Syndax Pharmaceuticals
3.0392 of 5 stars
$8.73
-3.0%
$35.80
+310.1%
-56.7%$774.43M$23.68M-2.26110Analyst Forecast
IMNM
Immunome
2.1209 of 5 stars
$8.69
-1.7%
$23.33
+168.5%
-25.7%$769.19M$9.04M-2.7340
GYRE
Gyre Therapeutics
0.2533 of 5 stars
$7.62
-6.3%
N/A-35.7%$762.25M$105.76M381.1940Positive News
VIR
Vir Biotechnology
3.6045 of 5 stars
$5.27
-2.6%
$32.86
+523.5%
-29.2%$747.87M$74.21M-1.25580News Coverage
Positive News
Analyst Forecast
DNA
Ginkgo Bioworks
0.8337 of 5 stars
$11.38
-10.5%
$5.77
-49.3%
N/A$744.53M$227.04M-1.24640News Coverage
Gap Down
XERS
Xeris Biopharma
3.8791 of 5 stars
$4.70
-1.1%
$6.25
+33.0%
+144.5%$742.83M$203.07M-15.67290
REPL
Replimune Group
4.0697 of 5 stars
$9.65
+2.7%
$20.83
+115.9%
+24.7%$724.61MN/A-3.14210High Trading Volume
PHAR
Pharming Group
2.358 of 5 stars
$10.47
-1.0%
$30.00
+186.5%
+17.2%$719.77M$297.20M-52.35280Gap Down
SANA
Sana Biotechnology
3.1426 of 5 stars
$3.10
-2.8%
$9.17
+195.7%
-21.6%$719.27MN/A-3.52380

Related Companies and Tools


This page (NASDAQ:FDMT) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners